阿斯利康首席执行官帕斯卡·索里奥（Pascal Soriot）周一告诉CNBC，Summit Therapeutics的主导药物可以帮助推动下一代癌症治疗组合，这可能是“癌症护理的未来”。“索里奥在接受CNBC独家采访时发表上述言论的一周前，这家制药巨头宣布与这家生物技术公司进行20亿美元的股权投资和临床合作，以测试潜在的癌症药物组合。
AstraZeneca CEO Pascal Soriot told CNBC on Monday that Summit Therapeutics' lead drug could help power next-generation cancer treatment combinations that could be the "future of cancer care." Soriot's comments in an exclusive interview with CNBC come a week after the pharmaceutical giant announced a $2 billion equity investment and clinical collaboration with the biotech company to test potential cancer drug combinations.
这项投资的核心是Summit的ivonescimab，这是一种一流的双特异性抗体，通过两种途径同时攻击癌症：PD-1，其作用就像免疫细胞的刹车，而血管内皮生长因子（一种帮助肿瘤生长新血管的信号）。
At the heart of that investment is Summit's ivonescimab, which is a first-in-class bispecific antibody that works by attacking cancer through two pathways simultaneously: PD-1, which acts like a brake on immune cells, and VEGF, a signal that helps tumors grow new blood vessels.
阻断两者都会释放人体免疫系统来攻击癌细胞，并切断肿瘤生长所需的血液供应。
Blocking both unleashes the body's immune system to attack cancer cells and cuts off the blood supply that tumors need to grow.
索里奥称这种药物是继最初一波仅针对PD-1的药物（例如默克公司的免疫疗法Keytruda）之后的“下一代”。在晚期非小细胞肺癌患者中，Ivonescimab的正面临床试验显示，它优于Keytruda（统治标准护理和历史上总收入最高的药物之一），在全球引起轰动。
Soriot called that medication the "next generation" after an initial wave of drugs that only target PD-1, such as Merck's immunotherapy Keytruda. Ivonescimab made waves globally after head-to-head clinical trials showed it outperformed Keytruda – the reigning standard of care and one of the highest-grossing drugs in history – in patients with advanced non-small cell lung cancer.
Soriot特别看到了将Summit的药物与阿斯利康称为抗体药物结合物的靶向癌症治疗组合结合的机会。
Soriot particularly sees an opportunity to combine Summit's drug with AstraZeneca's portfolio of targeted cancer treatments called antibody-drug conjugates.
Summit的药物“尤其非常令人兴奋，因为它可以帮助治疗某些类型的肿瘤，这些肿瘤可以与抗体-药物偶联物组合更好地治疗，比现有的第一代PD-1药物治疗效果更好，”他说。
Summit's drug "in particular is very exciting because it can help address a certain number of tumor types that can be better treated in combination with antibody-drug conjugates, better treated than with existing first-generation PD-1 agents," he said.
阿斯利康的投资相当于Summit约12%的股份，并且不是彻底的收购或许可协议。这意味着Summit保留了对ivonescimab的完全许可和商业权利，这引发了人们对以同样方式起作用的药物的巨大兴趣和数十亿美元的淘金热。
AstraZeneca's investment equates to a roughly 12% stake in Summit, and it's not an outright acquisition or licensing agreement. That means Summit retains full permission and commercial rights to ivonescimab, which has sparked massive interest and a multi-billion dollar gold rush into drugs that work the same way.
阿斯利康的新研发网站Soriot在马萨诸塞州剑桥市肯德尔广场的阿斯利康新的超过10亿美元的研发设施的网站上接受了CNBC的采访。
AstraZeneca's new R&D site Soriot spoke with CNBC from the site of AstraZeneca's new more than $1 billion research and development facility in Kendall Square in Cambridge, Massachusetts.
该公司周一宣布开放570，000平方英尺的场地，科学家将在那里开发下一代治疗肥胖，乳腺癌，COPD和罕见疾病等领域。阿斯利康表示，这些新产品将帮助公司在2030年以后实现增长。
The company on Monday announced the opening of the 570,000 square-foot site, where scientists will develop next-generation treatments across obesity, breast cancer, COPD and rare diseases, among other areas. AstraZeneca said those new products will help the company grow beyond 2030.
该中心将使用机器人技术，连续自动化和人工智能来帮助药物发现和开发过程。
The center will use robotics, continuous automation and agentic AI to aid the drug discovery and development process, the drugmaker added.
“这是更快，更低的研发成本，更多的产品被交付给更好的产品被交付给病人，”Soriot说。“我们正在与疾病作斗争，那里有很多未满足的需求。他说，该网站约20%的投资将用于机器人和人工智能。
"It's faster, lower cost of research and development, more products that are delivered to better products that are delivered to patients," Soriot said. "We are on the race against disease, and there's a lot of unmet needs out there." He said about 20% of the investment in the site is going toward robotics and AI.
“我们的想法是真正利用人工智能更快地发明新药，同时也投资机器人技术，以简化和加速在整个临床前阶段发现和开发分子的过程，”Soriot说。
"The idea is to really leverage AI to invent new medicines faster, but also invest in robotics to simplify and accelerate the process of discovering and developing molecules throughout the preclinical phase in particular," Soriot said.